ideasIdea
Treat immunotherapy side-effects without wiping out the response
Immune side-effects are usually treated with high-dose steroids, which may also switch off the anti-cancer response. Targeted alternatives may control the side-effect and keep the benefit.
High cumulative corticosteroid exposure for immune-related adverse events is associated with worse cancer outcomes in several cohorts, although confounding by severity is hard to exclude. Targeted alternatives — early infliximab or vedolizumab for colitis, tocilizumab for arthritis and some pneumonitis, topical or organ-directed therapy — could resolve toxicity with less systemic immunosuppression. A randomised comparison has never been done with cancer outcome as an endpoint.
Hypothesis
Targeted first-line immunosuppression for immune-related colitis achieves faster resolution and lower cumulative steroid dose than steroids, without reducing anti-tumour efficacy.
Rationale
Targeted agents already work as steroid rescue in refractory immune colitis, so efficacy on the toxicity is established; what is untested is whether using them first preserves the anti-tumour response. The trial also improves quality of life regardless of the survival result.
What would test it
A randomised trial in grade 2-3 immune-related colitis comparing steroid-first with targeted-first management, with time to resolution, cumulative steroid dose and subsequent progression-free survival as endpoints.
Maturity
early clinical
Who has to act
clinic
Cost to try
Medium ($1M to $50M)
Years to first evidence
5
Bottlenecks it attacks
- No one can predict who responds to immunotherapy · Checkpoint drugs cure some patients and do nothing for most. We still cannot tell the two apart before treating.
- Toxicity and quality of life are undervalued · Trials measure how long people live, not how they live. Side-effects are under-reported and under-treated.